---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-073763"
form_type: "8-K/A"
ticker: null
cik: "0001499785"
company_name: "Tengjun Biotechnology Corp."
filed_at: "2023-09-05T23:59:59+00:00"
generated_at: "2026-06-10T23:55:30.943386+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tengjun Biotechnology restates FY2022 financials; appoints Caihong Qu as interim CEO/CFO after CEO death

## Summary
- Board concluded FY2022 financial statements should no longer be relied upon due to accounting methodology errors.
- Auditor discovered discrepancies in Q2 review, citing errors in recognition, measurement, and recording.
- Company will amend FY2022 Form 10-K as soon as practicable to correct the errors.
- Caihong Qu, age 48, appointed as director, interim CEO and CFO effective August 10, 2023.
- Qu replaces Xianchang Ma, who passed away on August 3, 2023; she is his late wife.

## SEC filing metadata
- accession: 0001213900-23-073763
- form_type: 8-K/A
- cik: 0001499785
- company_name: Tengjun Biotechnology Corp.
- filed_at: 2023-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/0001213900-23-073763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/ea184679-8ka1_tengjun.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-073763
- JSON: https://secwatch.observer/filing/0001213900-23-073763.json
- Plain text: https://secwatch.observer/filing/0001213900-23-073763.txt

## Key facts
- Auditor Changes
  Tengjun Biotechnology Corp. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: On August 10, 2023, Tengjun Biotechnology Corp. (the "Company") announced that its Board of Directors (the "Board") concluded that the Company's previously issued financial statements, contained within its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, should no longer be relied upon due to accounting methodology errors in such financial statements and that the Board deems it advisable and in the best interests of the Company to restate the financial statements by amending its annual report on Form 10-K for the fiscal year ended December 31, 2022 as soon as reasonably practicable.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/0001213900-23-073763-index.htm
- Executive change
  Xianchang Ma departed as Director, Chief Executive Officer and Chief Financial Officer at Tengjun Biotechnology Corp..
  - Action: passed away
  - Role: Director, Chief Executive Officer and Chief Financial Officer
  source text: who passed away on August 3, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/0001213900-23-073763-index.htm
- Executive change
  Caihong Qu was appointed as Member of the Board at Tengjun Biotechnology Corp..
  - Action: appointed
  - Role: Member of the Board
  source text: On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/0001213900-23-073763-index.htm
- Executive change
  Caihong Qu was appointed as interim Chief Executive Officer and Chief Financial Officer at Tengjun Biotechnology Corp..
  - Action: appointed
  - Role: interim Chief Executive Officer and Chief Financial Officer
  source text: On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/0001213900-23-073763-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.